Virginia Life Sciences Investments (VLSI)

About

Portfolio · 3

BioProtect

Developer of a biodegradable balloon implant for prostate cancer radiation therapy.

2 rounds $3.4M committed Latest: 2016-06

Xenolith Medical

Angioplasty Retention and Navigation Technologies

1 round $1.0M committed Latest: 2011-01

Virtual Ports

Robotic and Multi-port Organ Manipulation During Laparoscopic Surgery

1 round $2.6M committed Latest: 2009-09

Investment activity

2 portfolio exits on record.

Q&A

What is Virginia Life Sciences Investments (VLSI)'s primary investment focus?

Virginia Life Sciences Investments (VLSI) specializes in biotechnology and life sciences, with a particular focus on surgical devices.

Which notable exits has Virginia Life Sciences Investments (VLSI) achieved?

Virginia Life Sciences Investments (VLSI) had an exit with BioProtect, which was acquired by Almeda Ventures for $200M in January 2026. Another exit was ImmunArray, acquired by Salveo Diagnostics in August 2019.

Who is a key team member at Virginia Life Sciences Investments (VLSI)?

Donna Edmonds is the CEO and a founder of Virginia Life Sciences Investments (VLSI).

What are some of Virginia Life Sciences Investments (VLSI)'s portfolio companies?

Virginia Life Sciences Investments (VLSI)'s portfolio includes BioProtect, which develops biodegradable balloons for radiation therapy, and Xenolith Medical, focused on angioplasty retention and navigation technologies.

When was Virginia Life Sciences Investments (VLSI) founded?

Virginia Life Sciences Investments (VLSI) was founded in 2009.

In which sector has Virginia Life Sciences Investments (VLSI) made the most investments?

Virginia Life Sciences Investments (VLSI) has made 5 rounds of investment in the Health Tech & Life Sciences sector, which is their primary focus.

What is the most recent exit for Virginia Life Sciences Investments (VLSI)?

The most recent exit for Virginia Life Sciences Investments (VLSI) was BioProtect, acquired by Almeda Ventures for $200M in January 2026.